[1]Illouz F., Laboureau-Soares S., Allix I., Rodien P. Modification de la fonction thyroïdienne par les inhibiteurs de tyrosine kinases. Corresp Metab Horm Diabetes Nutr. 2011;15:234-239. 7
[2]Vergès B. Effets métaboliques et endocriniens des thérapies ciblées en oncologie. Med Clin Endocrinol Diab 2015 ; 74 : 12-6.
[3]Illouz F., Braun D., Briet C., Schweizer U., Rodien P. Endocrine side-effects of anti-cancer drugs: thyroid effects of tyrosine kinase inhibitors. Eur J Endocrinol. 2014;171:R91-R99. 3
[4]Vergès B., Walter T., Cariou B. Endocrine side effects of anti-cancer drugs: effects of anti-cancer targeted therapies on lipid and glucose metabolism. Eur J Endocrinol. 2014;170:R43-R55. 2
[5]DeMatteo R.P., Ballman K.V., Antonescu C.R. Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373:1097-1104. 9669
[6]Ahmadieh H., Salti I. Tyrosine kinase inhibitors induced thyroid dysfunction: a review of its incidence, pathophysiology, clinical relevance, and treatment. Biomed Res Int. 2013;2013:725410.
[7]Harzstark A.L., Small E.J., Weinberg V.K. A phase 1 study of everolimus and sorafenib for metastatic clear cell renal cell carcinoma. Cancer. 2011;117:4194-4200. 18
[8]Desai J., Yassa L., Marqusee E. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med. 2006;145:660-664. 9
[9]Motzer R.J., Hutson T.E., Cella D. Pazopanib sunitinib in metastatic renal-cell carcinoma. N Engl J Med. 2013;369:722-731. versus8
[10]Tamaskar I., Bukowski R., Elson P. Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib. Ann Oncol. 2007;19:265-268. 2
[11]Kim T.D., Schwarz M., Nogai H. Thyroid dysfunction caused by second-generation tyrosine kinase inhibitors in Philadelphia chromosome-positive chronic myeloid leukemia. Thyroid. 2010;20:1209-1214. 11
[12]Ozao-Choy J., Ma G., Kao J., Wang G.X. The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res. 2009;69:2514-2522. 6
[13]Verloop H., Smit J.W., Dekkers O.M. Sorafenib therapy decreases the clearance of thyrotropin. Eur J Endocrinol. 2013;168:163-167. 2
[14]Mannavola D., Coco P., Vannucchi G. A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab. 2007;92:3531-3534. 9
[15]Funakoshi T., Shimada Y.J. Risk of hypothyroidism in patients with cancer treated with sunitinib: a systematic review and meta-analysis. Acta Oncol. 2014;52:691-702. 4
[16]Caron P., Gravis G., Oudard S., Pignot G. Gestion des effets secondaires des thérapies ciblées dans le cancer du rein : effets secondaires endocriniens et troubles métaboliques. Bull Cancer. 2011;98:S47-S59. 3
[17]Hutson T.E., Figlin R.A., Kuhn J.G., Motzer R.J. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist. 2008;13:1084-1096.
[18]Clemons J., Gao D., Naam M., Breaker K., Garfield D., Flaig T.W. Thyroid dysfunction in patients treated with sunitinib or sorafenib. Clin Genitourin Cancer. 2012;10:225-231. 4
[19]Grossmann M., Premaratne E., Desai J., Davis I.D. Thyrotoxicosis during sunitinib treatment for renal cell carcinoma. Clin Endocrinol (Oxf). 2008;69:669-672.
[20]Kollmannsberger C., Bjarnason G., Burnett P. Sunitinib in metastatic renal cell carcinoma: recommendations for management of noncardiovascular toxicities. Oncologist. 2011;16:543-553. 5